… a two-analyte acMMAE–MMAE population PK (popPK) model with covariate assessment
on each analyte, to support regulatory filing. A two-analyte integrated popPK model describing …

… The established two-analyte integrated population pharmacokinetic model was applied
to … factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-…

… Thus, population PK modeling to integrate the PK of … In summary, an integrated population
PK model was established … (pinatuzumab vedotin and polatuzumab vedotin) in patients with B-…

… a two-analyte acMMAE–MMAE population PK (popPK) model with covariate assessment
on each analyte, to support regulatory filing. A two-analyte integrated popPK model describing …

… pharmacokinetic and population pharmacokinetic modeling … This integrated model described
the complex PK of both … Confining popPK and ER analyses to only critical analytes greatly …

… analysis demonstrates that population pharmacokinetics and … a comprehensive understanding
of the pharmacokinetics … PK of polatuzumab vedotin was characterized by three analytes: …

… by the PBPK model were included in polatuzumab vedotin US prescribing information (…
Integrated twoanalyte population pharmacokinetic model for antibody-drug conjugates in patients…

… Population pharmacokinetic (popPK) analysis to assess PK in treatment-naïve versus R/R
NHL patients A two-analyte integrated popPK model that simultaneously describes …

… a two-analyte integrated population pharmacokinetic model … the pharmacokinetics of
polatuzumab vedotin in patients with … Polatuzumab vedotin population pharmacokinetics (popPK) …

… Three PK analytes were used to characterize polatuzumab vedotin PK (20, 22). Individual
PK parameters for antibody-conjugated MMAE, unconjugated MMAE, and total antibody in …